A Randomized Trial of Induction Versus Expectant Management
Trial ID or NCT#
Status
Purpose
A randomized clinical trial to assess whether elective induction of labor at 39 weeks of gestation compared with expectant management will improve outcomes.
Official Title
Induction in Nulliparous Women at 39 Weeks to Prevent Adverse Outcomes: A Randomized Controlled Trial
Eligibility Criteria
- 1. Nulliparous - no previous pregnancy beyond 20 weeks2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age.3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive based on clinical information and evaluation of the earliest ultrasound.
- 1. Project gestational age at date of first ultrasound is \> 20 weeks 6 days2. Plan for induction of labor prior to 40 weeks 5 days3. Plan for cesarean delivery or contraindication to labor4. Breech presentation5. Signs of labor (regular painful contractions with cervical change)6. Fetal demise or known major fetal anomaly7. Heparin or low-molecular weight heparin during the current pregnancy8. Placenta previa, accreta, vasa previa9. Active vaginal bleeding greater than bloody show10. Ruptured membranes11. Cerclage in current pregnancy12. Known oligohydramnios, defined as AFI \< 5 or MVP \< 213. Fetal growth restriction, defined as EFW \< 10th percentile14. Known HIV positivity because of modified delivery plan15. Major maternal medical illness associated with increased risk for adverse pregnancy outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac disease, renal insufficiency)16. Refusal of blood products17. Participation in another interventional study that influences management of labor at delivery or perinatal morbidity or mortality18. Delivery planned elsewhere at a non-Network site
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Cynthia Willson, RN, BSN
650-724-6372
View on ClinicalTrials.gov